Teva, OncoGenex unwind custirsen deal

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will pay OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) $27 million and return worldwide rights to custirsen sodium ( OGX-011)

Read the full 224 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE